In: Alcohol and alcoholism: the international journal of the Medical Council on Alcoholism (MCA) and the journal of the European Society for Biomedical Research on Alcoholism (ESBRA), Band 59, Heft 1
In: Bulletin of the World Health Organization: the international journal of public health = Bulletin de l'Organisation Mondiale de la Santé, Band 99, Heft 10, S. 750-752
In: Alcohol and alcoholism: the international journal of the Medical Council on Alcoholism (MCA) and the journal of the European Society for Biomedical Research on Alcoholism (ESBRA), Band 57, Heft 2, S. 152-154
In: Tetens , M M , Haahr , R , Dessau , R B , Krogfelt , K A , Bodilsen , J , Andersen , N S , Møller , J K , Roed , C , Christiansen , C B , Ellermann-Eriksen , S , Bangsborg , J M , Hansen , K , Benfield , T L , Andersen , C Ø , Obel , N , Omland , L H & Lebech , A-M 2020 , ' Changes in Lyme neuroborreliosis incidence in Denmark, 1996 to 2015 ' , Ticks and Tick-borne Diseases , vol. 11 , no. 6 , 101549 . https://doi.org/10.1016/j.ttbdis.2020.101549
Lyme neuroborreliosis (LNB) has recently been added to the list of diseases under the European Union epidemiological surveillance in order to obtain updated information on incidence. The goal of this study was to identify temporal (yearly) variation, high risk geographical regions and risk groups, and seasonal variation for LNB in Denmark. This cohort-study investigated Danish patients (n = 2791) diagnosed with LNB (defined as a positive Borrelia burgdorferi sensu lato (s.l.) intrathecal antibody test) between 1996–2015. We calculated incidence and incidence ratios of LNB by comparing 4-yr groups of calendar-years, area of residency, sex and age, income and education groups, and the number of new LNB cases per month. The incidence of LNB was 2.2 per 100,000 individuals and year in 1996−1999, 2.7 in 2004−2007 and 1.1 per 100,000 individuals in 2012−2015. Yearly variations in LNB incidence were similar for most calendar-year groups. LNB incidence was highest in Eastern Denmark and among males and individuals who were 0–14 yrs old, who had a yearly income of >449,000 DKK, and who had a Master's degree or higher education. The number of LNB cases was highest from July to November (p < 0.001). In conclusion, based on Danish nationwide data of patients with positive B. burgdorferi s.l. intrathecal antibody index (1996–2015) the incidence of LNB was found to increase until 2004−2007 but thereafter to decline. European surveillance studies of Lyme borreliosis should be encouraged to monitor the incidence trend.
In: Tetens , M M , Haahr , R , Dessau , R B , Krogfelt , K A , Bodilsen , J , Andersen , N S , Møller , J K , Roed , C , Christiansen , C B , Ellermann-Eriksen , S , Bangsborg , J M , Hansen , K , Benfield , T L , Andersen , C Ø , Obel , N , Omland , L H & Lebech , A M 2020 , ' Changes in Lyme neuroborreliosis incidence in Denmark, 1996 to 2015 ' , Ticks and Tick-borne Diseases , vol. 11 , no. 6 , 101549 . https://doi.org/10.1016/j.ttbdis.2020.101549
Lyme neuroborreliosis (LNB) has recently been added to the list of diseases under the European Union epidemiological surveillance in order to obtain updated information on incidence. The goal of this study was to identify temporal (yearly) variation, high risk geographical regions and risk groups, and seasonal variation for LNB in Denmark. This cohort-study investigated Danish patients (n = 2791) diagnosed with LNB (defined as a positive Borrelia burgdorferi sensu lato (s.l.) intrathecal antibody test) between 1996–2015. We calculated incidence and incidence ratios of LNB by comparing 4-yr groups of calendar-years, area of residency, sex and age, income and education groups, and the number of new LNB cases per month. The incidence of LNB was 2.2 per 100,000 individuals and year in 1996−1999, 2.7 in 2004−2007 and 1.1 per 100,000 individuals in 2012−2015. Yearly variations in LNB incidence were similar for most calendar-year groups. LNB incidence was highest in Eastern Denmark and among males and individuals who were 0–14 yrs old, who had a yearly income of >449,000 DKK, and who had a Master's degree or higher education. The number of LNB cases was highest from July to November (p < 0.001). In conclusion, based on Danish nationwide data of patients with positive B. burgdorferi s.l. intrathecal antibody index (1996–2015) the incidence of LNB was found to increase until 2004−2007 but thereafter to decline. European surveillance studies of Lyme borreliosis should be encouraged to monitor the incidence trend.
In: Tetens , M M , Haahr , R , Dessau , R B , Krogfelt , K A , Bodilsen , J , Andersen , N S , Møller , J K , Roed , C , Christiansen , C B , Ellermann-Eriksen , S , Bangsborg , J M , Hansen , K , Benfield , T L , Andersen , C Ø , Obel , N , Omland , L H & Lebech , A M 2020 , ' Changes in Lyme neuroborreliosis incidence in Denmark, 1996 to 2015 ' , Ticks and Tick-borne Diseases , vol. 11 , no. 6 , 101549 . https://doi.org/10.1016/j.ttbdis.2020.101549
Lyme neuroborreliosis (LNB) has recently been added to the list of diseases under the European Union epidemiological surveillance in order to obtain updated information on incidence. The goal of this study was to identify temporal (yearly) variation, high risk geographical regions and risk groups, and seasonal variation for LNB in Denmark. This cohort-study investigated Danish patients (n = 2791) diagnosed with LNB (defined as a positive Borrelia burgdorferi sensu lato (s.l.) intrathecal antibody test) between 1996–2015. We calculated incidence and incidence ratios of LNB by comparing 4-yr groups of calendar-years, area of residency, sex and age, income and education groups, and the number of new LNB cases per month. The incidence of LNB was 2.2 per 100,000 individuals and year in 1996−1999, 2.7 in 2004−2007 and 1.1 per 100,000 individuals in 2012−2015. Yearly variations in LNB incidence were similar for most calendar-year groups. LNB incidence was highest in Eastern Denmark and among males and individuals who were 0–14 yrs old, who had a yearly income of >449,000 DKK, and who had a Master's degree or higher education. The number of LNB cases was highest from July to November (p < 0.001). In conclusion, based on Danish nationwide data of patients with positive B. burgdorferi s.l. intrathecal antibody index (1996–2015) the incidence of LNB was found to increase until 2004−2007 but thereafter to decline. European surveillance studies of Lyme borreliosis should be encouraged to monitor the incidence trend.
In: Munch , M W , Meyhoff , T S , Helleberg , M , Kjær , M B N , Granholm , A , Hjortsø , C J S , Jensen , T S , Møller , M H , Hjortrup , P B , Wetterslev , M , Vesterlund , G K , Russell , L , Jørgensen , V L , Kristiansen , K T , Benfield , T , Ulrik , C S , Andreasen , A S , Bestle , M H , Poulsen , L M , Hildebrandt , T , Knudsen , L S , Møller , A , Sølling , C G , Brøchner , A C , Rasmussen , B S , Nielsen , H , Christensen , S , Strøm , T , Cronhjort , M , Wahlin , R R , Jakob , S M , Cioccari , L , Venkatesh , B , Hammond , N , Jha , V , Myatra , S N , Jensen , M Q , Leistner , J W , Mikkelsen , V S , Svenningsen , J S , Laursen , S B , Hatley , E V , Kristensen , C M , Al-Alak , A , Clapp , E , Jonassen , T B , Bjerregaard , C L , Østerby , N C H , Jespersen , M M , Abou-Kassem , D , Lassen , M L , Zaabalawi , R , Daoud , M M , Abdi , S , Meier , N , la Cour , K , Derby , C B , Damlund , B R , Laigaard , J , Andersen , L L , Mikkelsen , J , Jensen , J L S , Rasmussen , A H , Arnerlöv , E , Lykke , M , Holst-Hansen , M Z B , Tøstesen , B W , Schwab , J , Madsen , E K , Gluud , C , Lange , T & Perner , A 2021 , ' Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia : The COVID STEROID randomised, placebo-controlled trial ' , Acta Anaesthesiologica Scandinavica , vol. 65 , no. 10 , pp. 1421-1430 . https://doi.org/10.1111/aas.13941
Background: In the early phase of the pandemic, some guidelines recommended the use of corticosteroids for critically ill patients with COVID-19, whereas others recommended against the use despite lack of firm evidence of either benefit or harm. In the COVID STEROID trial, we aimed to assess the effects of low-dose hydrocortisone on patient-centred outcomes in adults with COVID-19 and severe hypoxia. Methods: In this multicentre, parallel-group, placebo-controlled, blinded, centrally randomised, stratified clinical trial, we randomly assigned adults with confirmed COVID-19 and severe hypoxia (use of mechanical ventilation or supplementary oxygen with a flow of at least 10 L/min) to either hydrocortisone (200 mg/d) vs a matching placebo for 7 days or until hospital discharge. The primary outcome was the number of days alive without life support at day 28 after randomisation. Results: The trial was terminated early when 30 out of 1000 participants had been enrolled because of external evidence indicating benefit from corticosteroids in severe COVID-19. At day 28, the median number of days alive without life support in the hydrocortisone vs placebo group were 7 vs 10 (adjusted mean difference: −1.1 days, 95% CI −9.5 to 7.3, P =.79); mortality was 6/16 vs 2/14; and the number of serious adverse reactions 1/16 vs 0/14. Conclusions: In this trial of adults with COVID-19 and severe hypoxia, we were unable to provide precise estimates of the benefits and harms of hydrocortisone as compared with placebo as only 3% of the planned sample size were enrolled. Trial registration: ClinicalTrials.gov: NCT04348305. European Union Drug Regulation Authorities Clinical Trials (EudraCT) Database: 2020-001395-15.
In: Munch , M W , Meyhoff , T S , Helleberg , M , Kjær , M B N , Granholm , A , Hjortsø , C J S , Jensen , T S , Møller , M H , Hjortrup , P B , Wetterslev , M , Vesterlund , G K , Russell , L , Jørgensen , V L , Kristiansen , K T , Benfield , T , Ulrik , C S , Andreasen , A S , Bestle , M H , Poulsen , L M , Hildebrandt , T , Knudsen , L S , Møller , A , Sølling , C G , Brøchner , A C , Rasmussen , B S , Nielsen , H , Christensen , S , Strøm , T , Cronhjort , M , Wahlin , R R , Jakob , S M , Cioccari , L , Venkatesh , B , Hammond , N , Jha , V , Myatra , S N , Jensen , M Q , Leistner , J W , Mikkelsen , V S , Svenningsen , J S , Laursen , S B , Hatley , E V , Kristensen , C M , Al-Alak , A , Clapp , E , Jonassen , T B , Bjerregaard , C L , Østerby , N C H , Jespersen , M M , Abou-Kassem , D , Lassen , M L , Zaabalawi , R , Daoud , M M , Abdi , S , Meier , N , la Cour , K , Derby , C B , Damlund , B R , Laigaard , J , Andersen , L L , Mikkelsen , J , Jensen , J L S , Rasmussen , A H , Arnerlöv , E , Lykke , M , Holst-Hansen , M Z B , Tøstesen , B W , Schwab , J , Madsen , E K , Gluud , C , Lange , T & Perner , A 2021 , ' Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia : The COVID STEROID randomised, placebo-controlled trial ' , Acta Anaesthesiologica Scandinavica , vol. 65 , no. 10 , pp. 1421-1430 . https://doi.org/10.1111/aas.13941
Background: In the early phase of the pandemic, some guidelines recommended the use of corticosteroids for critically ill patients with COVID-19, whereas others recommended against the use despite lack of firm evidence of either benefit or harm. In the COVID STEROID trial, we aimed to assess the effects of low-dose hydrocortisone on patient-centred outcomes in adults with COVID-19 and severe hypoxia. Methods: In this multicentre, parallel-group, placebo-controlled, blinded, centrally randomised, stratified clinical trial, we randomly assigned adults with confirmed COVID-19 and severe hypoxia (use of mechanical ventilation or supplementary oxygen with a flow of at least 10 L/min) to either hydrocortisone (200 mg/d) vs a matching placebo for 7 days or until hospital discharge. The primary outcome was the number of days alive without life support at day 28 after randomisation. Results: The trial was terminated early when 30 out of 1000 participants had been enrolled because of external evidence indicating benefit from corticosteroids in severe COVID-19. At day 28, the median number of days alive without life support in the hydrocortisone vs placebo group were 7 vs 10 (adjusted mean difference: −1.1 days, 95% CI −9.5 to 7.3, P =.79); mortality was 6/16 vs 2/14; and the number of serious adverse reactions 1/16 vs 0/14. Conclusions: In this trial of adults with COVID-19 and severe hypoxia, we were unable to provide precise estimates of the benefits and harms of hydrocortisone as compared with placebo as only 3% of the planned sample size were enrolled. Trial registration: ClinicalTrials.gov: NCT04348305. European Union Drug Regulation Authorities Clinical Trials (EudraCT) Database: 2020-001395-15.